Continual Reassessment Method for Partial Ordering

Much of the statistical methodology underlying the experimental design of phase 1 trials in oncology is intended for studies involving a single cytotoxic agent. The goal of these studies is to estimate the maximally tolerated dose, the highest dose that can be administered with an acceptable level o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biometrics 2011-12, Vol.67 (4), p.1555-1563
Hauptverfasser:	Wages, Nolan A., Conaway, Mark R., O'Quigley, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Antineoplastic Agents - toxicity BIOMETRIC METHODOLOGY Biometrics biometry Clinical trial Clinical trials Clinical Trials, Phase I as Topic - methods combination drug therapy Continual reassessment method Cytotoxicity Data Interpretation, Statistical Dosage Dose escalation Dose-finding studies Drug combination Drug combinations Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - etiology Estimation methods experimental design Experimentation Humans Maximum Tolerated Dose Neoplasms - drug therapy Oncology Outcome Assessment (Health Care) - methods Parametric models Partial ordering patients Phase 1 trials Probabilities Risk Assessment - methods Risk Factors Sample size Skeleton Statistical analysis Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!